Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling

Biochemical and Biophysical Research Communications

Volumn 457, Issue 3, 2015, Pages 445-450

  Maruyama, Akira ^a   Shime, Hiroaki ^a   Takeda, Yohei ^a   Azuma, Masahiro ^a   Matsumoto, Misako ^a   Seya, Tsukasa ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antitumor immunotherapy; Immunosuppression; Myeloid derive suppressor cells (MDSCs); Pam2 lipopeptides; Toll like receptor 2

Indexed keywords

LIPOPEPTIDE; PAM2CSK4; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; LIGAND; PAM2CSK4 LIPOPEPTIDE; TLR2 PROTEIN, MOUSE;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CELL ISOLATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; IN VIVO STUDY; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLEEN CELL; SUPPRESSOR CELL; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; DEFICIENCY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOMA; METABOLISM; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

MUS;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; IMMUNOTHERAPY; LIGANDS; LIPOPEPTIDES; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MYELOID CELLS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2; TUMOR MICROENVIRONMENT;

EID: 84922697043     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.011     Document Type: Article

References (36)

1. T. Kawai, S. Akira, The role of pattern-recognition receptors in innate immunity: update on toll-like receptors, Nat. Immunol. 11 (2010) 373-384, http://dx.doi.org/10.1038/ni.1863.
2. A. Mantovani, P. Allavena, A. Sica, F. Balkwill, Cancer-related inflammation, Nature 454 (2008) 436-444, http://dx.doi.org/10.1038/nature07205.
3. T. Akazawa, H. Masuda, Y. Saeki, M. Matsumoto, K. Takeda, K. Tsujimura, et al., Adjuvant-mediated tumor regression and tumor-specific cytotoxic response are impaired in MyD88-deficient mice, Cancer Res. 64 (2004) 757-764.
4. T. Seya, H. Shime, T. Ebihara, H. Oshiumi, M. Matsumoto, Pattern recognition receptors of innate immunity and their application to tumor immunotherapy, Cancer Sci. 101 (2010) 313-320, http://dx.doi.org/10.1111/j.1349-7006.2009.01442.x.
5. M. Azuma, R. Sawahata, Y. Akao, T. Ebihara, S. Yamazaki, M. Matsumoto, et al., The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation, PLoS ONE 5 (2010), http://dx.doi.org/10.1371/journal.pone.0012550.
6. R. Sawahata, H. Shime, S. Yamazaki, N. Inoue, T. Akazawa, Y. Fujimoto, et al., Failure of mycoplasma lipoprotein MALP-2 to induce NK cell activation through dendritic cell TLR2, Microbes Infect. 13 (2011) 350-358, http://dx.doi.org/10.1016/j.micinf.2010.12.003.
7. K.-Y. Shen, Y.-C. Song, I.-H. Chen, C.-H. Leng, H.-W. Chen, H.-J. Li, et al., Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells, J. Immunol. 192 (2014) 4233-4241, http://dx.doi.org/10.4049/jimmunol.1302850.
8. T.A. Wynn, A. Chawla, J.W. Pollard, Macrophage biology in development, homeostasis and disease, Nature 496 (2013) 445-455, http://dx.doi.org/10.1038/nature12034.
9. F. Chalmin, S. Ladoire, G. Mignot, J. Vincent, M. Bruchard, J.-P. Remy-Martin, et al., Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells, J. Clin. Invest 120 (2010) 457-471, http://dx.doi.org/10.1172/JCI40483.
10. H. Tye, C.L. Kennedy, M. Najdovska, L. McLeod, W. McCormack, N. Hughes, et al., STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation, Cancer Cell. 22 (2012) 466-478, http://dx.doi.org/10.1016/j.ccr.2012.08.010.
11. S. Kim, H. Takahashi, W.-W. Lin, P. Descargues, S. Grivennikov, Y. Kim, et al., Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis, Nature 457 (2009) 102-106, http://dx.doi.org/10.1038/ nature07623.
12. R.P.M. Sutmuller, M.H.M.G.M. den Brok, M. Kramer, E.J. Bennink, L.W.J. Toonen, B.-J. Kullberg, et al., Toll-like receptor 2 controls expansion and function of regulatory T cells, J. Clin. Invest 116 (2006) 485-494, http://dx.doi.org/10.1172/JCI25439.
13. S. Yamazaki, K. Okada, A. Maruyama, M. Matsumoto, H. Yagita, T. Seya, TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo, PLoS ONE 6 (2011) e18833, http://dx.doi.org/10.1371/journal.pone.0018833.
14. D.I. Gabrilovich, S. Ostrand-Rosenberg, V. Bronte, Coordinated regulation of myeloid cells by tumours, Nat. Rev. Immunol. 12 (2012) 253-268, http://dx.doi.org/10.1038/nri3175.
15. M.K. Srivastava, L. Zhu, M. Harris-White, U. Kar, U.K. Kar, M. Huang, et al., Myeloid suppressor cell depletion augments antitumor activity in lung cancer, PLoS ONE 7 (2012) e40677, http://dx.doi.org/10.1371/journal.pone.0040677.
16. B. Huang, P.-Y. Pan, Q. Li, A.I. Sato, D.E. Levy, J. Bromberg, et al., Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host, Cancer Res. 66 (2006) 1123-1131, http://dx.doi.org/10.1158/0008-5472.CAN-05-1299.
17. P. Serafini, S. Mgebroff, K. Noonan, I. Borrello, Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells, Cancer Res. 68 (2008) 5439-5449, http://dx.doi.org/10.1158/0008-5472.CAN-07-6621.
18. J.-I. Youn, S. Nagaraj, M. Collazo, D.I. Gabrilovich, Subsets of myeloid-derived suppressor cells in tumor-bearing mice, J. Immunol. 181 (2008) 5791-5802.
19. S.K. Bunt, V.K. Clements, E.M. Hanson, P. Sinha, S. Ostrand-Rosenberg, Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through toll-like receptor 4, J. Leukoc. Biol. 85 (2009) 996-1004, http://dx.doi.org/10.1189/jlb.0708446.
20. S. Ostrand-Rosenberg, P. Sinha, Myeloid-derived suppressor cells: linking inflammation and cancer, J. Immunol. 182 (2009) 4499-4506, http://dx.doi.org/10.4049/jimmunol.0802740.
21. P. Sinha, C. Okoro, D. Foell, H.H. Freeze, S. Ostrand-Rosenberg, G. Srikrishna, Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells, J. Immunol. 181 (2008) 4666-4675, http://dx.doi.org/10.4049/jimmunol.181.7.4666.
22. P. Cheng, C.A. Corzo, N. Luetteke, B. Yu, S. Nagaraj, M.M. Bui, et al., Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein, J. Exp. Med. 205 (2008) 2235-2249, http://dx.doi.org/10.1084/jem.20080132.
23. C. Zoglmeier, H. Bauer, D. Nörenberg, G. Wedekind, P. Bittner, N. Sandholzer, et al., CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice, Clin. Cancer Res. 17 (2011) 1765-1775, http://dx.doi.org/10.1158/1078-0432.CCR-10-2672.
24. Y. Shirota, H. Shirota, D.M. Klinman, Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells, J. Immunol. 188 (2012) 1592-1599, http://dx.doi.org/10.4049/jimmunol.1101304.
25. H. Shime, A. Kojima, A. Maruyama, Y. Saito, H. Oshiumi, M. Matsumoto, et al., Myeloid-derived suppressor cells confer tumor-suppressive functions onnatural killer cells via polyinosinic: polycytidylic acid treatment inmousetumormodels, J. Innate Immun. 6 (2014) 293-305, http://dx.doi.org/10.1159/000355126.
26. T. Akazawa, T. Ebihara, M. Okuno, Y. Okuda, M. Shingai, K. Tsujimura, et al., Antitumor NK activation induced by the toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 252-257, http://dx.doi.org/10.1073/pnas.0605978104.
27. H. Shime, M. Matsumoto, H. Oshiumi, S. Tanaka, A. Nakane, Y. Iwakura, et al., Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 2066-2071, http://dx.doi.org/10.1073/pnas.1113099109.
28. Y. Sawanobori, S. Ueha, M. Kurachi, T. Shimaoka, J.E. Talmadge, J. Abe, et al., Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice, Blood 111 (2008) 5457-5466, http://dx.doi.org/10.1182/blood-2008-01.
29. T. Condamine, D.I. Gabrilovich, Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function, Trends Immunol. 32 (2011) 19-25, http://dx.doi.org/10.1016/j.it.2010.10.002.
30. N. Sonda, M. Chioda, S. Zilio, F. Simonato, V. Bronte, Transcription factors in myeloid-derived suppressor cell recruitment and function, Curr. Opin. Immunol. 23 (2011) 279-285, http://dx.doi.org/10.1016/j.coi.2010.12.006.
31. J.I. Youn, M. Collazo, I.N. Shalova, S.K. Biswas, D.I. Gabrilovich, Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice, J. Leukoc. Biol. 91 (2012) 167-181, http://dx.doi.org/10.1189/jlb.0311177.
32. R.L. He, J. Zhou, C.Z. Hanson, J. Chen, N. Cheng, R.D. Ye, Serum amyloid A induces G-CSF expression and neutrophilia via toll-like receptor 2, Blood 113 (2009) 429-437, http://dx.doi.org/10.1182/blood-2008-03-139923.
33. X. Zhao, L. Rong, X. Zhao, X. Li, X. Liu, J. Deng, et al., TNF signaling drives myeloid-derived suppressor cell accumulation, J. Clin. Invest 122 (2012) 4094-4104, http://dx.doi.org/10.1172/JCI64115.
34. S.P. Hu, C. Harrison, K. Xu, C.J. Cornish, C.L. Geczy, Induction of the chemotactic S100 protein, CP-10, in monocyte macrophages by lipopolysaccharide, Blood 87 (1996) 3919-3928.
35. T. Kawai, S. Akira, Toll-like receptors and their crosstalk with other innate receptors in infection and immunity, Immunity 34 (2011) 637-650, http://dx.doi.org/10.1016/j.immuni.2011.05.006.
36. E. Vacchelli, A. Eggermont, C. Sautès-Fridman, J. Galon, L. Zitvogel, G. Kroemer, et al., Trial watch: toll-like receptor agonists for cancer therapy, Oncoimmunol 2 (2013) e25238, http://dx.doi.org/10.4161/onci.25238.